Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: Evidence for improved kidney graft outcome

Transplant Immunology

Volumn 31, Issue 3, 2014, Pages 145-151

  Savikko, Johanna ^a   Teppo, Anna Maija ^a   Taskinen, Eero ^a   von Willebrand, Eva ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic allograft injury; Cyclosporine; Kidney transplantation; Platelet derived growth factor; Tacrolimus

Indexed keywords

CYCLOSPORIN; PLATELET DERIVED GROWTH FACTOR; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT FAILURE; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY ALLOGRAFT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MACROPHAGE; MALE; NEPHROTOXICITY; NONHUMAN; RAT; TREATMENT OUTCOME; ALLOTRANSPLANTATION; ANIMAL; CELL CULTURE; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY; METABOLISM; PATHOLOGY; WISTAR FURTH RAT;

ANIMALS; CELLS, CULTURED; CHRONIC DISEASE; CYCLOSPORINE; FIBROSIS; GENE EXPRESSION REGULATION; GRAFT REJECTION; IMMUNOSUPPRESSION; KIDNEY; KIDNEY TRANSPLANTATION; MACROPHAGES; MALE; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, INBRED WF; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84922434041     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2014.08.003     Document Type: Article

References (35)

1. Dudley C., Pohanka E., Riad H., Dedochova J., Wijngaard P., Sutter C., et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the creeping creatinine study. Transplantation 2005, 79:466.
2. Chapman J.R. Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int Suppl 2005, 99:S108.
3. Paul L.C. Chronic allograft nephropathy - a model of impaired repair from injury?. Nephrol Dial Transplant 2000, 15:149.
4. Chapman J.R. Chronic calcineurin inhibitor nephrotoxicity - lest we forget. Am J Transplant 2011, 11:693.
5. Webster A.C., Woodroffe R.C., Taylor R.S., Chapman J.R., Craig J.C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 2005, 331:810.
6. Ekberg H., Bernasconi C., Tedesco-Silva H., Vítko S., Hugo C., Demirbas A., et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3years after transplantation. Am J Transplant 2009, 9:1876.
7. Meier M., Nitschke M., Weidtmann B., Jabs W.J., Wong W., Suefke S., et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006, 81:1035.
8. Marcard T., Ivens K., Grabensee B., Willers R., Helmchen U., Rump L.C., et al. Early conversion from cyclosporine to tacrolimus increases renal graft function in chronic allograft nephropathy at BANFF stages I and II. Transpl Int 2008, 21:1153.
9. Murphy G.J., Waller J.R., Sandford R.S., Furness P.N., Nicholson M.L. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Br J Surg 2003, 90:680.
10. Seron D., O'Valle F., Moreso F., Goma M., Hueso M., Grinyo J.M., et al. Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. Transplantation 2007, 83:649.
11. Mizuiri S., Iwamoto M., Miyagi M., Kawamura T., Sakai K., Arai K., et al. Activation of nuclear factor-kappa B and macrophage invasion in cyclosporin A- and tacrolimus-treated renal transplants. Clin Transplant 2004, 18:14.
12. Raftery M.J., Seron D., Koffman G., Hartley B., Janossy G., Cameron J.S. The relevance of induced class II HLA antigens and macrophage infiltration in early renal allograft biopsies. Transplantation 1989, 48:238.
13. Yehia M., Matheson J.M., Merrilees M.J., Beaumont B.W., Pilmore H.L. Predictors of chronic allograft nephropathy from protocol biopsies using histological and immunohistochemical techniques. Nephrology 2006, 11:261.
14. Palomar R., Ruiz J.C., Mayorga M., Escallada R., Zubimendi J.A., Cotorruelo J.G., et al. The macrophage infiltration index and matrix metalloproteinase-II expression as a predictor of chronic allograft rejection. Transplant Proc 2004, 36:2662.
15. Wieczorek G., Bigaud M., Menninger K., Riesen S., Quesniaux V., Schuurman H.J., et al. Acute and vascular rejection in nonhuman primate kidney transplantation. Am J Transplant 2006, 6:1285.
16. Floege J., Eitner F., Alpers C.E. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008, 19:12.
17. Savikko J., Taskinen E., von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003, 75:1147.
18. Savikko J., Rintala J.M., Rintala S.E., Koskinen P.K., von Willebrand E. Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. Nephrol Dial Transplant 2011, 26:3026.
19. Savikko J., Kallio E.A., Taskinen E., von Willebrand E. The effect of acute rejection and cyclosporin A-treatment on induction of platelet-derived growth factor and its receptors during the development of chronic rat renal allograft rejection. Transplantation 2002, 73:506.
20. Savikko J., Kallio E.A., von Willebrand E. Early induction of platelet-derived growth factor ligands nd receptors in acute rat renal allograft rejection. Transplantation 2001, 72:31.
21. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976, 17:565.
22. Bohman S.-O., Wilczek H.E., Reinholt F.P., von Willebrand E., Häyry P. Immunopathological patterns in long-term renal allografts. Transplantation 1991, 51:610.
23. Bennett W.M., DeMattos A., Meyer M.M., Andoh T., Barry J.M. Chronic cyclosporine nephropathy: the Achilles' heel of immunosupressive therapy. Kidney Int 1996, 50:1089.
24. Yilmaz S., Häyry P. The impact of acute episodes of rejection on the generation of chronic rejection in rat renal allografts. Transplantation 1993, 56:1153.
25. Troppmann C., Gillingham K.J., Benedetti E., Almond P.S., Gruessner R.W.G., Najarian J.S., et al. Delayed graft function, acute rejection, and outcome after cadaveric renal transplantation. The multivariety analysis. Transplantation 1995, 59:962.
26. Mennander A., Tiisala S., Paavonen T., Halttunen J., Häyry P. Chronic rejection of rat aortic allograft. II. Administration of cyclosporine induces accelerated allograft arteriosclerosis. Transpl Int 1991, 4:173.
27. Shin G.T., Khanna A., Ding R., Sharma V.K., Lagman M., Li B., et al. In vivo expression of transforming growth factor-β1 in humans: stimulation by cyclosporine. Transplantation 1998, 65:313.
28. Johnson D.W., Saunders H.J., Johnson F.J., Huq S.O., Field M.J., Pollock C.A. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor 1, transforming growth factor β1, and platelet-derived growth factor. J Pharmacol Exp Ther 1999, 289:535.
29. Mohamed M.A., Robertson H., Booth T.A., Balupuri S., Kirby J.A., Talbot D. TGF-β expression in renal transplant biopsies. A comparative study between cyclosporin-A and tacrolimus. Transplantation 2000, 69:1002.
30. Baboolal K., Jones G.A., Janezic A., Griffiths D.R., Jurewicz W.A. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002, 61:686.
31. von Willebrand E., Salmela K., Isoniemi H., Krogerus L., Taskinen E., Häyry P. Induction of HLA class II antigen and interleukin 2 receptor expression in acute vascular rejection of human kidney allografts. Transplantation 1992, 53:1077.
32. Croker B.P., Clapp W.L., Shamat A.R.F.A., Kone B.C., Peterson J.C. Macrophages and chronic allograft nephropathy. Kidney Int Suppl 1996, 57:S42.
33. Iacopino A.M., Doxey D., Cutler C.W., Nares S., Stoever K., Fojt J., et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol 1997, 68:73.
34. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002, 359:741. for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group.
35. Siegbahn A., Hammacher A., Westermark B., Heldin C.H. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990, 85:916.